The ESG Life Sciences Summit Europe, held in June brought together industry leaders to discuss how the life sciences sector can drive meaningful change through ESG initiatives. 

Gareth Collins, VP of Sustainability & EHS, presented our proactive approach to meeting the Corporate Sustainability Reporting Directive (CSRD) requirements and the importance of integrating sustainability reporting into business transformation strategy. 

Gareth also participated in a panel discussion on promoting sustainable practices in the biopharmaceutical industry. The panel explored how to measure environmental impact and identify key decarbonization strategies. It also discussed collective actions to engage employees in sustainability efforts and the importance of transparency through data-sharing across organizations. 

The summit provided a platform to showcase Generation Ipsen, our transformative sustainability strategy launched in 2022. Generation Ipsen is anchored by four key pillars: Environment, Patients, People, and Governance, reflecting Ipsen’s commitment to positive change. Our strategy includes significant achievements, such as reducing greenhouse gas emissions and promoting gender balance in leadership, underscoring our progress towards our 2023 sustainability targets. 

Our journey towards sustainability goes beyond regulatory compliance; we aim to lead the industry with innovative ESG approaches, fostering continuous improvement, and making a positive impact.  

When Eric Gratton joined Ipsen from a large financial services firm, he was surprised to find there wasn’t an employee resource group (ERG) dedicated to the LGBTQIA+ community. “Being the over-achiever I am, I thought I should start one: a little passion project for the community and its allies.” Taking inspiration from Elevate, Ipsen’s ERG for women, Eric began envisioning a global ERG. 

“We started with an event to brainstorm a name, set a charter, and define our values. We soft-launched Spectra last June during Pride month,” said Sam Baily. Ipsen in Cambridge, MA, was already collaborating with OUTbio, the biotech industry’s largest LGBTQIA+ professionals’ group, but the team was eager to do more. 

“Aline Stokes, our Global DE&I Director, introduced us, because she knew that as individuals, we had a shared passion for LGBTQIA+ inclusion. We became a team, and formed Spectra soon after,” Sam explained. “Our ambition is for Spectra to become a valued resource for employees and the business, including helping to shape Ipsen’s policies and, beyond that, influencing the broader healthcare and scientific communities. For example, working with healthcare providers to understand the importance of using the right pronouns and ensuring they are mindful of the patient’s experience.” 

“Courtney Anderson joined Spectra shortly after its inception. “I came into the organization as a strong LGBTQIA+ ally, and I’m proud of how far we’ve come as a group. We knew we needed help from our leadership to elevate our voices, and we are working with our North America Leadership Team sponsors. I am also working with OUTbio to plan an ERG Summit in the fall, and I’ve hosted events this year, including a panel discussion on how employers like Ipsen can play a key role in driving advocacy and change.” 

Beyond the North America chapter of Spectra, which has branches in Cambridge and Montreal, Spectra’s UK & Ireland branch is very active. Sam has been involved in DE&I projects for several years, including initiating a similar ERG in a previous company. “When I first joined Ipsen, there weren’t any ERGs, so I’ve seen a lot of change in the past few years. Initially, we had a group that focused broadly on diversity. With Spectra, we’re honing in on the LGBTQIA+ community, helping implement policies, and building awareness across Ipsen. When Spectra launched, there was a clear opportunity for us to collaborate closely and benefit from each other’s resources.” 

Spectra is guided by a clear vision, mission, and charter: 

Looking ahead, the co-chairs have ambitious goals beyond celebrating the community. They aim to develop policies for appropriate pronoun use, support transitioning employees, and improve benefits. “What we most need are people willing to step up and participate,” said Eric. “We want Spectra to be sustainable in the long-term,” added Courtney. “It needs to continue even if one day we aren’t here.” 

Looking forward to Spectra’s accomplishments in fostering inclusion and equity to create a supportive and diverse workplace for all. 

At the European Association for the Study of the Liver (EASL) congress, leading liver experts discuss the importance of proactive, personalized care and shared decision-making during consultations. A personalized care approach begins by listening to the patient’s feelings and needs, which can result in improved outcomes and quality of life for people living with primary biliary cholangitis (PBC). 

PBC is a rare and chronic autoimmune cholestatic liver disease with prevalence increasing worldwide.1-4 PBC causes chronic inflammation of the bile ducts. This leads to a build-up of bile and toxins in the liver (cholestasis), which results in scarring of the liver tissue (cirrhosis) and eventually liver failure.5,6 It can significantly impact a person’s quality of life (QoL) and, if left untreated, can result in the need for a liver transplant, and even premature death.2 Unfortunately, many people living with PBC describe that they feel unheard or excluded from the planning of their care.  

Wendy, who lives with PBC, describes the importance of involving patients in the care plan. “Doctors have never explained to me why they actually monitor the blood tests or what the numbers mean. If the patient understood the tests, their levels, and what it all means, they could better manage their PBC,” she shared. Wendy added “When I go and see the consultant, I would like to be listened to and understood. Just to listen to how I feel. Many people go to consultations and talk about various symptoms, but the consultant focuses only on PBC. However, PBC can trigger multiple symptoms and affect many aspects of life.”  

You can hear Wendy’s full story on the importance of individual’s involvement in their patient care plan to be part of the management of PBC, by viewing the full video below. 

“To develop an effective care plan for someone living with PBC, healthcare professionals must consider various perspectives, such as the risk of liver disease progression, the debilitating impact of PBC symptoms, and overall QoL. By embracing an individualized approach to PBC management, healthcare providers can better manage all aspects of the disease and its impact on daily life. This involves asking questions to understand the full extent of how PBC affects each patient and ensuring that patients feel empowered to express their experiences and fully grasp their care plans. When patients are heard and actively involved in their care plans, the complex and unique needs of people living with PBC can be addressed more effectively,” said Dr. Mark Swain, Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary.  

The Ipsen-sponsored symposium at the EASL congress, looks to address key challenges in managing PBC from both patient and physician perspectives. The panel discuss the path to proactive, personalized care in PBC and the importance of involving patients in treatment decisions.  


  1. Lv T, et al. J Gastroenterol Hepatol. 2021;36(6):1423–1434. 
  2. Galoosian A, et al. J Clin Transl Hepatol. 2020;8(1):49-60. 
  3. Lindor KD, et al. Hepatology. 2019;69(1):394-419. 
  4. Kumagi T & Heathcote EJ. Orphanet J Rare Di. 2008;3:1. 
  5. Younossi ZM, et al. Am J Gastroenterol. 2019;114(1):48–63. 
  6. Hirschfield GM, et al. Expert Rev Gastroenterol Hepatol. 2021;15(8):929-939 

A year of innovation and impact

In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3.128bn. These results demonstrate that our strategy is delivering, as we move away from reliance on a single blockbuster to further developing our four robust growth platforms.

Author Image

2023 marked the beginning of a new phase of growth. With four potential launches in 2024, we are focused on excellence, execution and rapidity. Our progress to date demonstrates that our strategy is delivering, leading to a stronger, more resilient Ipsen.

The acquisition of Albireo and the integration of over 25 new programs into our pipeline since 2020 will enable us to continue to deliver groundbreaking therapies to patients worldwide in the coming years.

Beyond financial achievements, we demonstrated a profound commitment to sustainability through our Generation Ipsen strategy. We achieved a 36% reduction in Scope 1 and 2 emissions and a 29% reduction in Scope 3 emissions, and set ambitious goals to become carbon neutral by 2025 and reach net-zero emissions by 2045.

Our journey in 2023 is a story of transformation, innovation, and unwavering dedication as we Focus. Together. For patients and society.

Discover more about our journey and innovations.

Together for Kidney Cancer is a global disease awareness initiative funded by Ipsen aiming to raise awareness of the reality of people’s experiences living with kidney cancer and the importance of shared decision making to inform better care outcomes.

Different people have different preferences and priorities when it comes to making decisions about their treatment and how it might impact their lives. Shared decision making helps people living with kidney cancer work with their healthcare providers to find a treatment plan that meets with their individual needs and preferences.

To address the need for greater uptake of shared decision making in practice, the Together for Kidney Cancer Action Plan was co-created with a select group of healthcare professionals, patient advocates, patients and carers within the kidney cancer community from around the world. It includes tangible actions that can be taken forward by members of the community, to support widespread adoption of shared decision making for the benefit of patients and healthcare systems.

From resources that help equip those living with kidney cancer to build confidence and participate in shared decision making, to training and healthcare infrastructure initiatives, there is something that everyone can do to pave the way for shared decision making for all those who want it.


Find out what actions you can take to support shared decision making in kidney cancer

Biodiversity encompasses the rich array of species and ecosystems vital for our planet’s health. Yet, human activities have endangered this diversity, jeopardizing not only various species but also our daily lives. Biodiversity is crucial for human health, providing essential services such as pollination, water purification, and climate regulation. Accelerating rates of biodiversity loss pose significant threats. Habitat destruction increases the risk of diseases originated in animals and then spread to humans, while disruptions to the food chain and loss of medicinal resources further endanger human well-being.  Recognizing this, the United Nations marks May 22nd as International Day for Biological Diversity (IDB) to raise awareness and spur action. This year’s theme, ‘Be part of the Plan,’ underscores the urgency to halt and reverse biodiversity loss.  

The Interconnection of Biodiversity and Climate Change 

Biodiversity and climate change are deeply intertwined. Climate change exacerbates habitat loss, making species more vulnerable to extinction. In turn, species loss disrupts carbon sequestration and alters ecosystems, worsening climate change. Addressing these challenges separately is not feasible; concerted efforts are needed to tackle both simultaneously. 

What can be done: conservation and climate change strategies 

At Ipsen, safeguarding the environment around our facilities is a paramount priority. Through our sustainability strategy, Generation Ipsen, we have developed a Biodiversity Strategy Plan (BSP) to address both biodiversity loss and climate change, striving to achieve “Nature Positive by 2030”.  

Since 2021, Ipsen’s biodiversity conservation efforts include ecological surveys and biodiversity data management to continuously enhance our environmental performance. In 2023, no protected species were recorded from the eDNA surveys and analysis. In addition, there were no species identified as threatened with extinction from the International Union for Conservation of Nature (IUCN) Red List of Threatened Species. Those that were recorded on the IUCN Red List database were all common species or identified as Least Concern. 

Our biodiversity commitment is fortified by maintaining Group certification to the ISO 14001-2015 Environmental Management system standard. Recent audits have validated our efforts, with no critical findings identified, ensuring the integrity of our environmental management system. Moreover, our pursuit of process efficiency has yielded tangible results, with notable reductions in air and waste-water emissions. 

Ipsen’s Nature and Biodiversity Certificate program aims to manage Ipsen’s sites for the benefit of nature. This involves implementing Biodiversity Action Plans to enhance on-site nature and transition towards more organic land management practices. Certificates are awarded at bronze, silver, gold, or platinum levels based on performance. The target is for all Ipsen-owned sites to achieve at least a silver level Nature and Biodiversity Certificate by 2025 and gold level by 2030. 

Furthermore, we’re actively engaging our teams in biodiversity discussions through various employee events, fostering a culture of environmental stewardship throughout Ipsen. Through community-based conservation initiatives like Generation Ipsen’s Community Days, Ipsen sites engage in habitat enhancement and partnerships with external conservation organizations.  

These commitments reflect Ipsen’s ongoing dedication to both environmental sustainability and biodiversity conservation. They pave the way for a future where our operations seamlessly integrate with the natural world. 

Sandra Silvestri, Executive Vice President & Chief Medical Officer at Ipsen, reflects on the challenges women living with primary biliary cholangitis (PBC) face and why we have big dreams of a better future for PBC.

At the time of Mother’s Day in the United States, I was reflecting on the multifaceted role that many women play within families. 

As a Medical Doctor, Executive and Mother myself, on a daily basis I am trying to be the best Mother I can be to my children, while at the same time juggling career, work, life admin, and attending to the whole family’s needs.  

What had really been occupying my thoughts at this time though, was if I find some days a challenge, how must it be for those women who are living with primary biliary cholangitis (PBC).  

PBC is a rare, progressive, autoimmune cholestatic liver disease that predominantly affects women aged 40-60 years of age. In fact, 90% of people impacted by PBC are women.1 One of the main symptoms of PBC is chronic fatigue. Another is intense itching, which can affect sleep, exacerbating the fatigue further. 2,3 

I have had the opportunity to listen to some of the women living with PBC, who have been kind enough to share their experiences with us at Ipsen. This is such a privilege, as it helps me and my colleagues to understand what is really important to patients and the outcomes they would like to achieve from a treatment. It helps us to direct our research, our clinical trials, and the evidence we need to collect, to ensure our treatments address the true unmet needs of those living with PBC. 

Understanding the challenges for people impacted by PBC 

In people with PBC, the body attacks and gradually destroys the liver’s small bile ducts. If left untreated, bile and toxins may build up, called cholestasis, leading to scarring of the liver, known as cirrhosis, and eventually liver failure.4  

There is also a lot of clinical evidence about the negative impact that symptoms of PBC can have on a person’s quality of life.2,3 This includes fatigue, which affects 95% of patients2,3, intolerable itching, also known as pruritus, affecting 70% of patients3, and other autoimmune diseases such as Sjogren’s syndrome.5 It is also reported that PBC symptoms can lead to depression, sleep deprivation and suicidal ideation.6 

For many of those living with PBC, the challenges do not stop with the symptoms, and it is not uncommon to face delays in getting a diagnosis. Not only this but once you have been diagnosed, available treatments do not always effectively manage the disease progression or address the symptoms that impact on quality of life.7,8,9  

When you think of all of these challenges, it comes as no surprise that PBC can have a substantial impact on every aspect of quality of life.2,3 Therefore, measuring this impact has quickly become one of the most important factors when assessing how we can help those living with PBC by facilitating improved medical care, optimizing treatment outcomes, and improving everyday life.10 

Parenting with PBC: Navigating the journey with strength and resilience  

As my colleagues and I engage with these inspiring individuals living with rare liver disease, hear their stories, and look at how we can stop the disease to progress and improve their quality of life, we recognize that PBC’s impact extends far beyond the individual—it reverberates through families. 

Sabrina is one of these inspiring individuals, a mother and a grandmother living with PBC. In a conversation with Sabrina, she shared with us that she “functions at a three to five level of pain every day” and that each day differs depending on the severity of her symptoms. However, this does not stop her from spending time with her family and doing the things she loves the most, highlighting that “You need to make every moment count and I want to live life while I can live it. I want to have those experiences with my family. I want to do those things with my kids and grandkids. Don’t give up hope.” 

Trying to be the best parent you can be while living with a condition like PBC is a momentous ask, and Sabrina’s story resonates with other individuals out there who are navigating life with a long-term disease, whilst also raising their children. These are the experiences and challenges that drive us at Ipsen: we are doctors and scientists but we are first of all mums, dads, sons, daughters, grandparents, grandchildren, siblings, and friends who have been deeply moved by Sabrina’s story and that of other people living with rare liver disease. 

Beyond today: Envisioning a bright future with PBC 

When I think about the journey of those living with PBC, it really hits home how much more we need to do. For nearly a decade, there has been a lack of innovation in PBC, and we need treatments that not only work but also address the associated challenges of living with rare liver disease. Recent innovations can only be beneficial and will ensure that every patient has the chance to optimize their outcomes, reduce their risk of disease progression and preserve their quality of life. 

At Ipsen, we are ordinary people who dream big.  

We are dedicated to developing new transformative treatment options that both manage the disease progression and address the effects of symptoms of rare liver disease. We are on a mission to get these treatments into the hands of those who need them most, right when they need them.  

I’m proud to say that we are here to drive the change that’s long overdue in the world of treatment innovation. We will not stop for as long as we have the potential to change the lives of people like Sabrina, and the outlooks of all those impacted by rare liver disease. 

Listen to Sabrina’s story of navigating rare liver disease, along with many other inspiring stories here.


Sandra Silvestri, M.D., Ph.D.

Executive Vice President, Chief Medical Officer


  1. Galoosian A, et al. 2020. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol. 8(1), pp. 49-60.
  2. Mells GF, et al. 2013. Impact of Primary Biliary Cholangitis on Perceived Quality of Life: The UK-PBC National Study. Hepatol. 58: 273-283.
  3. C Levy, et al. 2023. Understanding the Experience of Patients with Primary Biliary Cholangitis and Pruritus. Abstract presented at ISPOR, 7-11 May 2023, Boston.
  4. Tanaka A. 2021. Current understanding of primary biliary cholangitis.Clin Mol Hepatol.27(1), pp. 1–21.
  5. Chalifoux SL, et al. 2017. Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut. 15;11(6):771-780.
  6. Gungabissoon U, et al. 2022. Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. BMJ Open Gastroenterol. 9(1), p.e000857.
  7. Ali AH, Byrne TJ, Lindor KD. 2015. Orphan drugs in development for primary biliary cirrhosis: challenges and progress. Orphan Drugs: Research and Reviews. 5(1), pp..83-97.
  8. Corpechot C, et al. 2011. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 55:1361-7.
  9. Aguilar MT and Chascsa DM. 2020. Update on emerging treatment options for primary biliary cholangitis. Hepat Med. Pp.69-77.
  10. Gimenez-Lozano C, et al. 2022. Rare Diseases: Needs and Impact for Patients and Families: A Cross-Sectional Study in the Valencian Region, Spain. Int J Environ Res Public Health.19(16):10366.

To mark World Clinical Trials Day, we sat down with Christelle Huguet, Executive Vice President, Head of R&D at Ipsen to explore the importance of diversity from all sides of the research and development process, as we accelerate innovation.  

Hi Christelle! Health inequities pose one of the most pressing public health challenges of our time. How can improving diversity and inclusion within research and development help address these disparities?

To me health equity means that everyone around the world has access to innovative treatments that are both safe and effective, regardless of their ethnicity, gender, age, disability, language, or any other distinguishing characteristic. To achieve this, novel treatments must be validated in different demographics, since they may respond differently to medicines for genetic, physiological, and environmental reasons. At Ipsen we make purposeful choices to enhance clinical trial diversity, including the number and location of trial sites, however underrepresentation persists, particularly amongst minority or marginalized communities who experience many barriers to participation. This means that there is a real opportunity to help improve health equity by improving clinical trial diversity. But we must also take a step back and acknowledge the importance of greater diversity across the full spectrum of the healthcare ecosystem – from community organizations, policy makers and regulators to healthcare providers and researchers – we all have a part to play.

It sounds like collaboration is really important for us to make progress. How does Ipsen encourage diversity and inclusion and what impact does this have on the R&D process?

Diverse teams bring a variety of perspectives, beliefs and experiences to the table which helps fosters a culture of creativity, innovation and responsibility. At Ipsen we source our pipeline exclusively through external innovation, a strategy which recognizes the value of uniting varied expertise from across our R&D teams and the biotechs and academic centers with which we partner.

Within research, this can increase our chances of making new scientific discoveries and help us to design and execute robust, ethical and comprehensive development processes. Diverse representation facilitates a deeper understanding of the barriers preventing clinical trial participation, ensuring protocols and recruitment processes are sensitive and inclusive.

We also routinely engage with patient organizations to inform our development programs. Their extensive knowledge of patient communities means they are able to provide invaluable insights and considerations that can help us remove barriers and promote equitable participation in studies for all individuals.

Ultimately, increasing diversity starts with fostering an environment of inclusivity, where all individuals feel welcomed and respected, with their unique contributions encouraged. As an industry, we are making great strides to encourage diversity however, there is still work to be done which is why we have set out clear, actionable D&I targets as part our Generation Ipsen commitment.

What other steps is Ipsen taking to contribute to this transformation and what challenges do you face?

We are continually expanding our network of trial sites to more countries, but also to beyond the big centers, where access to healthcare and clinical leads is limited. Ipsen currently has the first ever trial site in China for investigating treatments for Fibrodysplasia Ossificans Progressiva (FOP) which is helping us to diversify the data we collect for this ultra rare disease. However, because at Ipsen our focus is on rare diseases and niche indications we face unique challenges to increasing clinical trial diversity. In this setting, where clinical trial participant numbers are limited, as we introduce a greater range of genders, ages, ethnicities and co-morbidities, the quality and strength of data collected could be impacted through drop-out or small numbers (e.g. sub-populations). We must therefore carefully balance increasing diversity with the ability to draw clear and statistically significant conclusions from the data, or otherwise risk not meeting primary endpoints and preventing a potentially life-changing medicine from reaching any patients at all. There are a number of ways our teams at Ipsen are exploring these challenges, including how we can push the boundaries of biostatistics to process diverse data, identify small trends and prevent bias. We are also looking more closely at what we measure and optimizing secondary exploratory endpoints to fully understand subpopulations. Ultimately, if you start by building a diverse team and prioritising inclusivity, the rest should follow.

Finally, when considering the new FDA legal requirements aimed at improving clinical trial diversity, how will Ipsen ensure it meets these criteria moving forwards? Ensuring diversity in clinical trials is not only scientifically necessary, but also ethically imperative, and Ipsen is committed to playing our part in this journey. Over the coming year, a strong focus for our R&D team will be critically assessing how we approach trial design, protocol development, participant recruitment and data analysis to inform the development of a clear strategy on how we can continue to encourage greater diversity in our trials.


Christelle Huguet

Executive Vice President, Head of R&D


Progressive Familial Intrahepatic Cholestasis (PFIC) is a rare liver disease that can pose significant challenges, particularly in young children1, but the good news is that there are growing opportunities to manage the disease, slow its progression and improve outcomes.  

A new standard of care for diagnosing and managing PFIC was enthusiastically discussed by leading liver experts at this year’s European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Congress in May. 

PFIC represents a spectrum of genetic disorders that cause a build-up of bile in the liver and can be particularly aggressive in babies and infants. If left untreated, PFIC can lead to end-stage liver failure and necessitate a liver transplant.1,2 Pruritus (intolerable itching), is the most burdensome symptom of PFIC and, in some cases, can be so severe that it leads to skin mutilation, loss of sleep, irritability, poor attention, and impaired school performance.1 

PFIC is a progressive condition, where damage to the liver can continue without effective management, so early diagnosis and management are vital.4,5 We spoke to an Associate Professor of the Paediatric and Liver Unit at Anna Meyer Children’s University-Hospital, Dr Indolfi, who highlighted that: “We have the numbers saying that a good number of these children with PFIC could have a worse outcome, but early diagnosis, early treatment, early management of this disease can of course improve the long-term natural history of the disease.” You can find out more about PFIC symptoms and the importance of early treatment by viewing the full film here.  

Throughout ESPGHAN, the liver experts reinforced that any children presenting with symptoms, such as jaundice, severe itching, failure to thrive, and irritability should raise suspicions of PFIC to avoid unnecessary delays in diagnosis. A quick referral should follow these suspicions so treatment can be initiated as soon as possible, with a focus on improving clinical symptoms and slowing disease progression to delay the need for liver transplantation.  

While PFIC is commonly associated with children, it can also appear in adults. For one form of PFIC, symptoms often mimic other diseases that affect the flow of bile through the liver, making it difficult to initially diagnose.6 Therefore, it’s important to consider PFIC when looking into cholestatic conditions because it can easily go unnoticed.  

If you recognize any of these signs or symptoms, speak to your doctor as soon as possible. Early detection and management can make a significant difference in the course of PFIC. For more information, visit the PFIC Network website.   



  1. Baker A, et al. Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2019. 43:20-36. 
  2. Mighiu C, et al. Impact of progressive familial intrahepatic cholestasis on caregivers: caregiver-reported outcomes from the multinational PICTURE study. Orphanet J. Rare Dis. 2022. 17:1-9. 
  3. Folmer DE, et al. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatol (Baltimore, Md.). 2009. 50(5), 1597–1605. 
  4. Jones-Hughes T, et al. Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review. Orphanet J. Rare Dis. 2021.16(1), 255.  
  5. McKiernan P, et al. Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis. JHEP Rep. 2023. 6(1),100949.  
  6. Srivastava A. Progressive familial intrahepatic cholestasis. JCEH. 2014. 4(1), 25–36.  

Ipsen 2024 Annual General Meeting

The Ipsen S.A. 2024 Annual General Meeting took place on  28 May 2024, in Paris, France.

Annual General Meeting Replay (in French only)

Annual General Meeting Replay (in French only)